Gadolinium-DOTA enhanced MR imaging of prostatic lesions. Preliminary results on 14 cases.
Fourteen patients with prostatic carcinoma, benign prostatic hyperplasia, or chronic granulomatous prostatitis underwent gadolinium-DOTA enhanced magnetic resonance imaging of the prostate. Gadolinium-DOTA was administered intravenously in a dosage of 0.1 mmol/kg body weight. All studies were performed on a superconductive 1.5-T system. As compared to noncontrast T1- and T2-weighted images, Gd-DOTA enhanced T1-weighted images were useful in distinguishing malignant tumor from granulomatous prostatitis in one case, but were uncontributive to the differentiation between carcinoma and benign prostatic hyperplasia.
Gevenois
P A
PA
Department of Radiology, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Brussels, Belgium.
Sintzoff
S A
SA
Stallenberg
B
B
Salmon
I
I
Simon
J
J
Van Regemorter
G
G
Struyven
J
J
D003287:Contrast Media; D005682:Gadolinium; D006571:Heterocyclic Compounds; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D009942:Organometallic Compounds; D011469:Prostatic Diseases / Q000175:diagnosis*; D011470:Prostatic Hyperplasia / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000175:diagnosis; D011472:Prostatitis / Q000175:diagnosis
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate; D005682:Gadolinium